Objectives: The cost-effectiveness of fracture prevention treatments (vitamin D and calcium and hip protectors) in male and female populations older than seventy years of age in the United-Kingdom was investigated.

Methods: A Markov model was developed to follow up, over lifetime, a hypothetical cohort of males and females at high-risk and general risk of fracture. Patients could sustain hip, wrist, vertebral, and/or other fractures. Fracture rates were obtained from population surveys in the United Kingdom. Effectiveness and quality of life data were identified from the clinical literature. Costs were those incurred by the UK National Health Service, and were obtained from several published sources. Uncertainty was explored through probabilistic sensitivity analysis.

Results: In the general-risk female (male) population, the incremental cost per Quality Adjusted Life Year (QALY) was $11,722 ($47,426) for hip protectors. In the male high-risk population, the incremental cost per QALY was $17,017 for hip protectors. In the female high-risk population, hip protectors were cost-saving. Vitamin D and calcium alone was dominated by hip protectors in all four subgroups.

Conclusions: Current information available on interventions to prevent fractures in the elderly in the United Kingdom, suggests that, at the decision-maker's ceiling ratio of $20,000 per QALY, hip protectors are cost-effective in the general female population and high-risk male population, and cost-saving in the high-risk female population, despite the low compliance rate with the treatment.

Objective: To characterize the net cost and quality of life effects associated with hip protector use among the elderly relative to no intervention.

Methods: We developed two deterministic hypothetical cohorts of 500,000 65-year-old women or men and followed them over the remainder of their lifetimes. Data inputs were collected from secondary sources. Net costs are expressed in 1999 U.S. dollars, whereas net effectiveness is expressed in lives saved and in quality-adjusted life-years (QALYs) gained.

Results: Hip protector use results in net cost savings for both elderly women and men. Women over age 65 and men over age 85 also gain QALYs through hip protector use.

Conclusions: Using the estimates available in the literature, our analysis indicates that use of hip protectors among women is associated with large cost savings and QALY gains even when accounting for the inconvenience of using the protectors. Among men, hip protectors are also associated with cost savings (although of smaller magnitude), but there are net losses of QALYs because of the inconveniences associated with the protectors.